Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.49 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | FLT1 | P17948 | 4/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.48 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 4/20 | 0.48 |
| ▸ | KIF5B | P33176 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5654431 | 0.90 | KDR (0.54) | KDRSRCEGFRFLT1RET | |
| SCHEMBL5650880 | 0.87 | KDR (0.63) | KDRSRCEGFRFLT1FGFR1 | |
| SCHEMBL5652496 | 0.86 | KDR (0.59) | KDREGFRFLT1FGFR1KDM1A | |
| SCHEMBL5649679 | 0.86 | KDR (0.53) | KDRSRCEGFRFLT1FGFR1 | |
| SCHEMBL5651331 | 0.85 | KDR (0.64) | KDREGFRFLT1FGFR1KDM1A | |
| SCHEMBL5652946 | 0.85 | KDR (0.57) | KDRSRCEGFRFLT1FGFR1 | |
| SCHEMBL5650381 | 0.85 | KDR (0.52) | KDRSRCEGFRFLT1FGFR1 | |
| SCHEMBL5649566 | 0.84 | EGFR (0.57) | KDRSRCMAPK14EGFRFLT1 | |
| SCHEMBL5653774 | 0.84 | KDR (0.57) | KDREGFRFLT1FGFR1KDM1A | |
| SCHEMBL5651269 | 0.83 | KDR (0.56) | KDREGFRFLT1FGFR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | claimed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | claimed |
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | KDR 1/4885SRC 960/4885MAPK14 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.